Market cap $175.14M
Enterprise value $136.36M
Employees 407
Revenue $105M
EBITDA -$37.5M
Income -$46.4M
EPS -2.05
P/E N/A
Forward P/E -2.82
EV/EBITDA -3.64
PEG N/A
Earnings date 2018-03-07
Volume 58.2k / 157k
Relative vol. 0.37 ×
Profit margin -44.24%
Oper. margin -38.79%
Gross margin 53.61%
Ret. on assets -20.39%
Return on equity -240.97%
Sales Q/Q 7.07%
Sales Y/Y 34.84%
Est. EPS Q/Q N/A
Beta -0.20
Mean Recomm. 2.40
IPO year 2013
Country United States
RSI 48.74
Range $6.70 – $6.95
52 weeks $6.31 – $20.70
SMA 50 $8 +9.64%
SMA 200 $11 +52.86%
1 year target $11 +62.32%

Intraday

5 days

1 month

3 months

6 months

1 year

5 years

10 years

All time

Monday, 5 February 2018
-3.04%
globenewswire
NanoString Announces Largest and Most Comprehensive Study to Date of Prosigna Breast Cancer Assay Published in Journal of Clinical Oncology
Friday, 26 January 2018
-1.54%
globenewswire
New Research: Key Drivers of Growth for NanoString Technologies, Oaktree Capital Group, Midstates Petroleum, GlycoMimetics, State Street, and Retail Properties of America — Factors of Influence, Major Initiatives and Sustained Production
Friday, 19 January 2018
+0.00%
globenewswire
NanoString Reports Inducement Grant Under NASDAQ Listing Rules
Tuesday, 16 January 2018
-2.86%
globenewswire
NanoString Appoints Thomas Bailey as Chief Financial Officer
Monday, 8 January 2018
+2.44%
globenewswire
NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2017
Thursday, 4 January 2018
+3.57%
globenewswire
NanoString and RikenGenesis Announce Partnership to Commercialize nCounter-Based Diagnostic Assays in Japan
Tuesday, 19 December 2017
-0.91%
simplywall.st
NanoString Technologies Inc : Should The Recent EPS Drop Worry You?
Thursday, 7 December 2017
+0.00%
globenewswire
NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hematology
Thursday, 9 November 2017
+5.88%
globenewswire
NanoString Highlights Record Number of nCounter-Based Research Abstracts at the 2017 Annual Meeting of the Society of Immunotherapy of Cancer
nasdaq
NanoString Highlights Record Number of nCounter-Based Research Abstracts at ...
Thursday, 2 November 2017
-1.11%
ap
NanoString reports 3Q loss
reuters
Nanostring Technologies reports Q3 loss per share $0.45
globenewswire
NanoString Technologies Releases Operating Results for Third Quarter of 2017
accesswire
NanoString Technologies, Inc. to Host Earnings Call
Wednesday, 1 November 2017
-0.60%
nasdaq
Cutera, Inc. Names Elisha Wade Finney to its Board of Directors
Tuesday, 31 October 2017
+2.68%
simplywall.st
Is NanoString Technologies Inc Undervalued?
Thursday, 26 October 2017
+7.36%
globenewswire
NanoString and the NSABP Foundation Enter into Agreement to Study Immunophenotypes in Colorectal Cancer
Friday, 13 October 2017
-2.13%
accesswire
Today’s Research Reports on Trending Tickers: AcelRx Pharmaceuticals and NanoString Technologies
Thursday, 12 October 2017
-7.83%
nasdaq
Mid-Day ETF Update: ETFs, Stocks Mixed as Hurricanes' Impact on PPI Sours ...
nasdaq
Mid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals ...
nasdaq
Mid-Day Market Update: J.Jill Tumbles Following Weak Q3 Outlook; Ardelyx ...
nasdaq
Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates
seekingalpha
Premarket analyst action - healthcare
Wednesday, 11 October 2017
+0.06%
reuters
NanoString posts preliminary revenue for Q3 2017
globenewswire
NanoString Announces Preliminary Revenue for Third Quarter of Fiscal Year 2017
Monday, 18 September 2017
-0.19%
globenewswire
NanoString’s Hyb & Seq™ Enables Liquid Biopsy by the Direct Capture and Sequencing of Cell-Free DNA
nasdaq
NanoString's Hyb & Seq™ Enables Liquid Biopsy by the Direct Capture and ...
Friday, 15 September 2017
-2.70%
nasdaq
Levin Capital Strategies, Lp Buys Tyson Foods Inc, General Electric Co ...
Thursday, 7 September 2017
+0.71%
globenewswire
NanoString to Webcast Presentation at the 2017 Morgan Stanley Global Healthcare Conference
nasdaq
NanoString to Webcast Presentation at the 2017 Morgan Stanley Global ...
Tuesday, 5 September 2017
+0.26%
globenewswire
Anthem Issues Positive Coverage Decision for NanoString’s Prosigna® Breast Cancer Assay
Thursday, 31 August 2017
-0.06%
globenewswire
NanoString to Webcast Presentation at the 2017 Baird Global Healthcare Conference
Wednesday, 30 August 2017
+2.18%
reuters
NanoString Technologies Inc files for mixed shelf of up to $100 million - SEC filing ‍​
Tuesday, 8 August 2017
+0.79%
ap
NanoString reports 2Q loss
reuters
Nanostring Technologies Inc says co entered into collaboration agreement with Lam Research Corporation- SEC Filing
globenewswire
NanoString and Lam Research Announce Strategic Development Collaboration to Advance Hyb & Seq Next Generation Sequencing Platform
nasdaq
NanoString Technologies Releases Operating Results for Second Quarter of 2017
reuters
NanoString Technologies Q2 loss per share $0.20
reuters
Nanostring Technologies signs‍ collaboration agreement with Lam Research
accesswire
Investor Network: NanoString Technologies, Inc. to Host Earnings Call
Monday, 10 July 2017
-0.19%
nasdaq
Mettler-Toledo Appoints Elisha Finney to Board of Directors
nasdaq
NanoString to Release Second Quarter 2017 Financial Results and Host ...
Wednesday, 5 July 2017
-0.37%
nasdaq
Mettler-Toledo International Inc. Announces Elisha Finney to Join Board of ...
Monday, 19 June 2017
+1.52%
marketwatch
Single-Cell Analysis Market Worth 3.59 Billion USD by 2022
Thursday, 1 June 2017
+2.33%
nasdaq
Health Care Sector Update for 06/01/2017: NSTG,DXTR,MBOT
nasdaq
BUZZ-US STOCKS ON THE MOVE-Signet, CenturyLink, Express, Minerva, casino stocks
reuters
BRIEF-NanoString Technologies announces pricing of offering of 3 mln shares of ...
reuters
NanoString Technologies announces pricing of offering of 3 mln shares of common stock
Wednesday, 31 May 2017
+0.55%
reuters
NanoString announces offering of common stock
Thursday, 4 May 2017
+3.58%
reuters
Nanostring Technologies Q1 loss per share $0.87
Wednesday, 1 March 2017
+0.16%
reuters
Nanostring Technologies Q4 loss per share $0.55
Tuesday, 10 January 2017
-12.24%
reuters
NanoString Technologies provides preliminary operational and financial results for 2016
Wednesday, 2 November 2016
-5.35%
reuters
Nanostring Technologies Q3 loss per share $0.51
Wednesday, 3 August 2016
+1.65%
reuters
Nanostring Technologies- operating results for Q2 of 2016
Monday, 18 July 2016
-1.52%
reuters
James Tananbaum reports 5.9 pct passive stake in Nanostring Tech
Thursday, 5 May 2016
-0.06%
reuters
NanoString Technologies Inc reiterates FY 2016 guidance
Monday, 29 February 2016
-3.53%
reuters
NanoString Technologies Inc gives FY 2016 guidance
reuters
NanoString Technologies and Merck Expand Collaborationand Merck Expand Collaboration
Monday, 2 November 2015
+1.30%
reuters
NanoString Technologies Inc reaffirms FY 2015 revenue guidance; lowers FY 2015 EBIT guidance
Tuesday, 4 August 2015
+1.96%
reuters
NanoString Technologies Inc raises FY 2015 revenue outlook; lowers FY 2015 EBIT outlook
Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2016-12-23 R Bradley Gray
President and CEO
President and CEO Option exercise 8,000 $1.92 $15,360
2016-12-23
67,768
2016-12-05 Wayne Burns
SVP, Operations & Admin
SVP, Operations & Admin Option exercise 21,666 $12.80 $277,325
2016-12-05
70,040
2016-11-21 Charles P Jr Waite
Director
Director Sale 588,024 $21.25 $12,495,510
2016-11-21
0
2016-11-10 Barney Saunders
SVP, Sales & Marketing
SVP, Sales & Marketing Sale 11,983 $22.48 $269,378
2016-11-10
1,670
2016-11-10 James A Johnson
Chief Financial Officer
Chief Financial Officer Option exercise 10,000 $5.12 $51,200
2016-11-10
9,480
2016-11-10 R Bradley Gray
President and CEO
President and CEO Sale 37,325 $22.49 $839,439
2016-11-10
59,768
2016-10-26 Charles P Jr Waite
Director
Director Sale 42,489 $20.56 $873,574
2016-10-26
588,024
2016-09-07 Wayne Burns
SVP, Operations & Admin
SVP, Operations & Admin Sale 3,961 $16.50 $65,357
2016-09-07
59,704
2016-09-06 Charles P Jr Waite
Director
Director Sale 29,105 $16.51 $480,524
2016-09-06
527,109
2016-08-26 Charles P Jr Waite
Director
Director Sale 111,060 $16.57 $1,840,264
2016-08-26
556,214
2016-08-23 Charles P Jr Waite
Director
Director Sale 40,363 $16.59 $669,622
2016-08-23
667,274
2016-08-18 Charles P Jr Waite
Director
Director Sale 72,145 $16.61 $1,198,328
2016-08-18
707,637
2016-08-12 Charles P Jr Waite
Director
Director Sale 257,698 $16.55 $4,264,902
2016-08-12
779,782
2016-03-01 David W. Ghesquiere
SVP, Corporate & Business Dev
SVP, Corporate & Business Dev Option exercise 5,000 $0.00 $0
2016-03-01
7,521

Notable SEC filings of NanoString Technologies, Inc.

Date Contents
Source
2017-11-08 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-11-08 10-Q Quarterly report
2017-11-02 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-10-11 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-08-09 10-Q Quarterly report
2017-08-08 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-08-08 8-K Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Statements and Exhibits
2017-06-23 8-K Submission of Matters to a Vote of Security Holders
2017-06-02 8-K Other Events; Financial Statements and Exhibits
2017-05-18 8-K Results of Operations and Financial Condition; Other Events
2017-05-10 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits
2017-05-05 10-Q Quarterly report
2017-05-04 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-04-28 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2017-03-09 10-K Yearly report
2017-03-01 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2017-02-22 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events
2017-01-10 8-K Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits
2017-01-06 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
2016-11-04 10-Q Quarterly report
2016-11-02 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-09-13 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Financial Statements and Exhibits
2016-08-04 10-Q Quarterly report
2016-08-03 8-K Results of Operations and Financial Condition; Financial Statements and Exhibits
2016-07-19 8-K Submission of Matters to a Vote of Security Holders
2016-05-06 10-Q Quarterly report
Outperform Baird 2 November 2017
Outperform → Market Perform
Cowen & Co. 11 October 2017
Buy → Neutral
Janney Capital 11 October 2017
Equal-Weight
Morgan Stanley 19 April 2017

NanoString Technologies executives

Insider Title Age Since Compensation
R. Bradley Gray (40)
President, Chief Executive Officer, Director since 2010
President, Chief Executive Officer, Director 40 2010 $1,695,760
David Ghesquiere (50)
Senior Vice President - Corporate & Business Development since 2013
Senior Vice President - Corporate & Business Development 50 2013 $1,600,570
Joseph Beechem (59)
Senior Vice President - Research and Development since 2012
Senior Vice President - Research and Development 59 2012 $512,524
Kirk Malloy (50)
Independent Director since 2016
Independent Director 50 2016 $167,383
William Young (72)
Independent Chairman of the Board since 2010
Independent Chairman of the Board 72 2010 $139,080
Charles Waite (61)
Independent Director since 2004
Independent Director 61 2004 $110,080
Gregory Norden (59)
Independent Director since 2012
Independent Director 59 2012 $107,580
Nicholas Galakatos (59)
Independent Director since 2009
Independent Director 59 2009 $103,580
Robert Hershberg (51)
Independent Director since 2015
Independent Director 51 2015 $91,580
Elisha Finney (55)
Director since 2017
Director 55 2017
Mary Allen (54)
Senior Vice President - Operations since 2017
Senior Vice President - Operations 54 2017
J. Chad Brown
Senior Vice President - Sales and Marketing since 2017
Senior Vice President - Sales and Marketing 2017
K. Thomas Bailey (50)
Chief Financial Officer, Treasurer since 2018
Chief Financial Officer, Treasurer 50 2018
NanoString Technologies, Inc. logo

NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.

  • NanoString Technologies, Inc., 530 Fairview Avenue North, Seattle 98109, United States
  • nanostring.com
  • 206-378-6266

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

Balance sheet

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Current assets
Cash $28.797 $40.647 $5.416 $20.583
Short term investments $61.051 $58.69 $51.724 $53.453
Net receivables $18.288 $18.482 $16.728 $22.193
Inventory $18.52 $15.759 $14.544 $13.812
Other current assets $6.109 $5.305 $3.953 $3.744
Total current assets $132.765 $138.883 $92.365 $113.785
Long term investments
Property, plant & equipment $13.867 $13.644 $13.657 $12.158
Goodwill
Intangible assets
Other assets $0.555 $0.515 $0.511 $0.43
Deferred long term asset charges
Total assets $147.187 $153.042 $106.533 $126.373
Current liabilities
Accounts payable $22.436 $15.379 $11.262 $17.279
Short long term debt $0.026 $0.058
Other current liabilities $17.157 $17.511 $21.135 $19.046
Total current liabilities $39.593 $32.89 $32.423 $36.383
Long term debt $48.533 $48.137 $47.748 $47.366
Other liabilities
Deferred long term liabilities $13.991 $19.991 $29.419 $30.319
Minority interest
Total liabilities $102.117 $101.018 $109.59 $114.068
Stockholders' equity
Stock option warrants
Common stock $0.002 $0.002 $0.002 $0.002
Retained earnings -$304.351 -$292.947 -$288.392 -$269.54
Treasury stock
Capital surplus $349.447 $345.022 $285.381 $281.9
Other stockholder equity -$0.028 -$0.053 -$0.048 -$0.057
Total stockholder equity $45.07 $52.024 -$3.057 $12.305
Net tangible assets $45.07 $52.024 -$3.057 $12.305
(in millions) 2016 2015 2014
Current assets
Cash $20.583 $21.856 $17.223
Short term investments $53.453 $27.188 $55.002
Net receivables $22.193 $19.725 $12.436
Inventory $13.812 $10.138 $5.444
Other current assets $3.744 $3.886 $5.114
Total current assets $113.785 $82.793 $95.219
Long term investments
Property, plant & equipment $12.158 $9.414 $6.366
Goodwill
Intangible assets
Other assets $0.43 $0.481 $0.483
Deferred long term asset charges $0.181
Total assets $126.373 $92.869 $102.068
Current liabilities
Accounts payable $17.279 $15.424 $13.783
Short long term debt $0.058 $0.226 $0.251
Other current liabilities $19.046 $5.261 $4.774
Total current liabilities $36.383 $20.911 $18.808
Long term debt $47.366 $41 $29.995
Other liabilities
Deferred long term liabilities $30.319 $10.743 $8.452
Minority interest
Total liabilities $114.068 $72.654 $57.255
Stockholders' equity
Stock option warrants
Common stock $0.002 $0.002 $0.002
Retained earnings -$269.54 -$222.451 -$176.87
Treasury stock
Capital surplus $281.9 $242.693 $221.724
Other stockholder equity -$0.057 -$0.029 -$0.043
Total stockholder equity $12.305 $20.215 $44.813
Net tangible assets $12.305 $20.215 $44.813

Income statement

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Revenue
Total revenue $27.016 $34.593 $18.063 $25.232
Cost of revenue $7.305 $8.224 $7.163 $8.429
Gross profit $19.711 $26.369 $10.9 $16.803
Operating expenses
Research & development $11.374 $11.038 $10.801 $9.996
Selling, general & administrative $18.38 $18.645 $17.565 $16.682
Non-recurring
Other operating expenses
Total operating expenses
Operating income -$10.043 -$3.314 -$17.466 -$9.875
Income from continuing operations
Net other income $0.24 $0.334 $0.16 -$0.153
EBIT -$9.803 -$2.98 -$17.306 -$10.028
Interest expense $1.556 $1.528 $1.501 $1.522
Income before tax -$11.359 -$4.508 -$18.807 -$11.55
Income tax expense $0.045 $0.047 $0.045 $0.043
Minority interest
Net income from continuing ops -$11.404 -$4.555 -$18.852 -$11.593
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$11.404 -$4.555 -$18.852 -$11.593
Income (for common shares) -$11.404 -$4.555 -$18.852 -$11.593
(in millions) 2016 2015 2014
Revenue
Total revenue $86.489 $62.667 $47.593
Cost of revenue $30.245 $26.126 $21.149
Gross profit $56.244 $36.541 $26.444
Operating expenses
Research & development $34.72 $24.597 $21.404
Selling, general & administrative $62.7 $53.186 $51.063
Non-recurring
Other operating expenses
Total operating expenses
Operating income -$41.176 -$41.242 -$46.023
Income from continuing operations
Net other income -$0.125 -$0.156 $0.125
EBIT -$41.301 -$41.398 -$45.898
Interest expense $5.672 $4.017 $4.14
Income before tax -$46.973 -$45.415 -$50.038
Income tax expense $0.116 $0.166
Minority interest
Net income from continuing ops -$47.089 -$45.581 -$50.038
Non-recurring events
Discontinued operations
Extraordinary items
Effect of accounting change
Other items
Net income
EBITDA -$47.089 -$45.581 -$50.038
Income (for common shares) -$47.089 -$45.581 -$50.038

Cash flow

(in millions) 2017Q3 2017Q2 2017Q1 2016Q4
Net income -$11.404 -$4.555 -$18.852 -$11.593
Operating activities
Depreciation $0.852 $0.836 $0.903 $0.652
Net income adjustments $3.669 $3.451 $2.668 $2.921
Change in accounts receivable $0.037 -$1.951 $5.466 -$1.156
Changes in liabilities $0.781 -$8.458 -$5.729 $2.866
Changes in inventory -$3.399 -$1.635 -$0.837 -$2.322
Changes in other operating activities -$0.873 -$1.388 $1.115 $2.182
Total cash flow from operations -$10.337 -$13.7 -$15.266 -$6.43
Investing activities
Capital expenditures -$0.421 -$0.891 -$2.493 -$1.282
Investments -$2.37 -$6.961 $1.65 -$10.274
Other cash flows from investing
Total cash flows from investing -$2.791 -$7.852 -$0.843 -$11.556
Financing activities
Dividends paid
Sale and purchase of stock $1.333 $56.799 $1.214 $28.16
Net borrowings -$0.026 -$0.032 -$0.034
Other cash flows from financing -$0.061 -$0.061 -$0.248 -$0.248
Total cash flows from financing $1.272 $56.773 $0.934 $28.126
Effect of exchange rate $0.006 $0.01 $0.008 -$0.025
Change in cash and equivalents -$11.856 $35.221 -$15.175 $10.14
(in millions) 2016 2015 2014
Net income -$47.089 -$45.581 -$50.038
Operating activities
Depreciation $2.957 $2.647 $1.676
Net income adjustments $10.531 $7.4 $5.574
Change in accounts receivable -$2.476 -$7.328 -$4.109
Changes in liabilities $31.668 $0.869 $12.897
Changes in inventory -$5.035 -$5.354 -$1.252
Changes in other operating activities $3.345 $3.985 -$2.809
Total cash flow from operations -$6.079 -$43.362 -$38.061
Investing activities
Capital expenditures -$3.991 -$3.796 -$1.9
Investments -$26.274 $27.559 -$22.434
Other cash flows from investing $0.004 $0.006 $0.059
Total cash flows from investing -$30.261 $23.769 -$24.275
Financing activities
Dividends paid
Sale and purchase of stock $30.319 $14.539 $58.55
Net borrowings $4.774 $9.729 $11.786
Other cash flows from financing
Total cash flows from financing $35.093 $24.268 $69.566
Effect of exchange rate -$0.026 -$0.042 $0.052
Change in cash and equivalents -$1.247 $4.675 $7.23
Messenger